Nov 5, 2024 07:05AM
Feb 12, 2024 07:38AM
Feb 12, 2024 07:37AM
Dec 11, 2023 03:52AM
Dec 10, 2023 12:00PM
Dec 5, 2023 06:33AM
Dec 5, 2023 06:30AM FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
Nov 30, 2023 07:31AM
Nov 30, 2023 07:30AM
Nov 2, 2023 06:30AM
Oct 27, 2023 06:30AM
Oct 27, 2023 06:30AM
Oct 5, 2023 04:13PM
Sep 28, 2023 07:02AM Immunogen (IMGN) Announces ELAHERE Shows Overall and PFS Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer
Sep 28, 2023 07:00AM
Sep 18, 2023 06:30AM
Sep 18, 2023 06:30AM
Aug 28, 2023 06:30AM
Aug 28, 2023 06:30AM
Jul 31, 2023 06:35AM
Jul 31, 2023 06:35AM ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer
Jul 31, 2023 06:30AM
Jun 9, 2023 05:28AM
Jun 9, 2023 03:00AM
Jun 5, 2023 05:57AM
Jun 4, 2023 08:00AM
May 9, 2023 06:30AM
May 9, 2023 06:30AM ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting
May 3, 2023 10:19AM
May 3, 2023 07:35AM
May 3, 2023 06:41AM
May 3, 2023 06:30AM
Apr 28, 2023 06:30AM
Apr 24, 2023 06:30AM
Apr 24, 2023 06:30AM ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer
Apr 6, 2023 06:33AM
Apr 6, 2023 06:30AM
Mar 1, 2023 06:30AM
Dec 28, 2022 04:31PM
Dec 28, 2022 04:30PM
Dec 10, 2022 10:30AM
Dec 9, 2022 06:42AM Immunogen (IMGN), Gilead (GILD) to collaborate on pivekimab/magrolimab combo for AML
Dec 9, 2022 06:30AM
Nov 21, 2022 06:04AM
Nov 18, 2022 09:22AM
Nov 18, 2022 09:20AM
Nov 14, 2022 05:52PM
Nov 14, 2022 04:30PM
Nov 14, 2022 04:30PM ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
Nov 4, 2022 06:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All